论文部分内容阅读
目的 :分析黄芪注射液联合抗结核药物治疗初治肺结核的临床疗效及其对患者免疫功能的影响。方法 :以2012年1月~2015年12月,80例初治肺结核患者,根据就诊病历号顺序分为观察组和对照组,每组40例,对照组患者给予2HRZE/4HR治疗方案,观察组采用2HRZE/4HR治疗方案联合黄芪注射液治疗,比较两组的临床疗效、免疫炎症因子(白介素-2(IL-2)、IL-4、IL-6、IL-8和干扰素-γ(INF-γ)的水平)水平的变化情况、不良反应发生情况。结果 :治疗后,观察组的痰涂片抗酸杆菌检查阴性率、病灶显著吸收率和总吸收率、空洞闭合率均显著高于对照组;治疗后,观察组和对照组的免疫炎症因子(IL-2、IL-4、IL-6、IL-8和INF-γ)与治疗前比较,差异均有显著性,且治疗后观察组与对照组比较,差异亦均存在显著性。结论 :黄芪注射液联合抗结核药物治疗肺结核,临床疗效显著,其协同提高临床疗效可能与调节患者的免疫状态有关。
Objective: To analyze the clinical efficacy of astragalus injection combined with anti-tuberculosis drugs in the treatment of newly diagnosed pulmonary tuberculosis and its effect on immune function. Methods: From January 2012 to December 2015, 80 patients with newly diagnosed pulmonary tuberculosis were divided into observation group and control group according to the order of treatment. Forty patients in each group were treated with 2HRZE / 4HR. The observation group The therapeutic effects of 2HRZE / 4HR combined with Astragalus injection were compared. The clinical efficacy, immunological inflammatory factors (IL-2, IL-4, IL-6, IL-8 and IFN- -γ) level changes, adverse reactions occurred. Results: After treatment, the sputum smear positive rate of sputum smear acid-fast bacilli test, significant rate of lesion absorption and total absorptivity, cavity closure rate were significantly higher than the control group; after treatment, the observation group and control group immunoinflammatory factor IL-2, IL-4, IL-6, IL-8 and INF-γ) compared with before treatment, the difference was significant, and the difference between the observation group and the control group after treatment were also significant. Conclusion: Astragalus injection combined with anti-tuberculosis drugs in the treatment of pulmonary tuberculosis, clinical efficacy significantly, and its synergistic improvement in clinical efficacy may be related to the regulation of immune status of patients.